Skip to main contentPsst! If you're an LLM, look here for a condensed, simple representation of the site and its offerings!

LiveFree Webinar — Wednesday, September 30 at 2:00 PM EDT

Register Free →

PCI SYNTHESIS

UEI: KFEGN12NLNG1

PCI SYNTHESIS is a federal contractor, registered under UEI KFEGN12NLNG1. It has been awarded $75,900 across 1 federal contract. Primary work spans Pharmaceutical Preparation Manufacturing. Top awarding agencies include Department Of Health And Human Services.

Contact Information

Registration and classification details

Registration

UEI Code

KFEGN12NLNG1

Federal Contracting Overview

Award totals, agency breakdown, NAICS distribution, and geographic footprint.

Key Performance Metrics

Awards Count

0

All time

Active

0

Currently performing

Completed

0

Past period of performance

Total Awards

All time

Contracts

Prime · all time

Subcontracts

Sub · all time

Grants

Prime · all time

Subgrants

Sub · all time

Award Analytics & Distribution

Awards by Agency
Department Of Health And Human Services$75.9K100%
Awards by NAICS
325412 - Pharmaceutical Preparation Manufacturing$75.9K100%
Awards by Agency Over Time
Awards by Place of Performance

Compete with PCI SYNTHESIS

Track the contractors you bid against, and the work they win

Award history, agency mix, and NAICS coverage for PCI SYNTHESIS

AI-powered matching against your own capabilities and past performance

Teaming and subcontracting signals on every award

Automated alerts when a competitor wins in your market

Miguel
Hillary
Keith Deutsch
Christine

Join 750+ contractors already using CLEATUS

Open opportunities in PCI SYNTHESIS's top NAICS codes and agencies

NAICS: 325412
New
Federal
Piflufolastat F-18 injection drugs (Pylarify) from Lantheus (Notice of Intent to sole source)
Solicitation # NOI-27-000004
The National Institutes of Health Clinical Center intends to award a sole-source contract to Progenics Pharmaceuticals Inc., a Lantheus company, for the procurement of Piflufolastat F-18 injection (Pylarify). This FDA-approved radiopharmaceutical is used for the scintigraphic localization of prostate-specific membrane antigen positive lesions in men with prostate cancer. Due to the rapid radiation decay and short half-lives of the drug, it must be compounded, calibrated, and delivered as patient-ready unit doses on demand to the NIH Clinical Center Nuclear Pharmacy Facility in Bethesda, Maryland. The procurement is justified under FAR 8.405-6(b) and 41 U.S.C. 1901(a)(1) because Progenics Pharmaceuticals is the sole authorized provider and intellectual property owner capable of meeting the highly specialized quality and regulatory requirements of the FDA and the U.S. Nuclear Regulatory Commission. The contract is structured as an Indefinite Delivery/Indefinite Quantity requirement for 150 to 230 injections and four unused dose fees. The period of performance consists of a base year from October 1, 2026, to September 30, 2027, with four subsequent option years extending through September 30, 2031. The award will be made using GSA Contract 36F79719D0170 and includes an economic price adjustment clause per FAR 52.216-2 for 2026 pricing. Performance is measured by the accuracy of delivered doses, the absence of contamination, and strict adherence to federal regulatory standards.
National Institutes Of Health - Cc

POSTED

about 22 hours ago

DEADLINE

in 6 days
View Details